Background Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare
variants of pituitary tumors for which no evidence-based treatment currently exists. We …

Abstract Purpose Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are
challenging for their invasive nature, resistance to treatment and recurrences …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1)
staining index of 3% or more, and positive immunohistochemical staining for p53 protein …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Although aggressive pituitary adenomas (PAs) have been proposed and widely discussed
for more than a decade, there is no general agreement regarding their definition, diagnosis …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Introduction Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal
multimodality therapy. The challenge lies in their early recognition and timely management …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …